Pregabalin Capsule
Product Images NDC 82804-170

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82804-170). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-170-60 (Image 01)

Packaging label for Pregabalin 75 mg capsules by Proficient Rx LP, containing 60 capsules. The label states each capsule contains 75 mg Pregabalin and describes the capsule as light peach opaque cap and white opaque body, size 4 hard gelatin with imprints '140' on the cap and 'J' on the body. It includes storage instructions and manufacturer details from Hetero Labs Limited, India, along with barcodes, a QR code, and regulatory markings including C-V and RX only.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares different dosages of Pregabalin (200 mg, 100 mg, and 25 mg three times a day) and placebo, illustrating the effectiveness of various doses in pain improvement over a range of percent improvement values.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A line chart comparing the estimated percentage of subjects without LTR over time (in days) between Pregabalin and placebo groups. The x-axis represents days up to 180, and the y-axis represents the estimated percentage of subjects without LTR, showing a higher rate maintained in the Pregabalin group compared to placebo.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph showing the percent of subjects improved over time from baseline to week 12 measured by BOCF. The x-axis represents percent improvement and the y-axis represents percent of subjects improved. Two lines compare Pregabalin with Placebo, showing higher improvement percentages for Pregabalin across the range.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph comparing the percent of subjects improved over time from baseline to Week 16, showing results for Pregabalin versus Placebo. The x-axis represents the percent improved, and the y-axis shows the percent of subjects improved, with two lines depicting Pregabalin and Placebo outcomes across the study period.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Two lines compare Pregabalin 100 mg three times a day and placebo, showing higher improvement rates for Pregabalin.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares several groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, showing differences in pain improvement percentages across these groups.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph comparing the percent improvement in pain from baseline against the percent of patients improved for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows trends in patient response across different levels of pain improvement.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The vertical axis represents the percent of patients improved from 0 to 100%, and the horizontal axis shows percent improvement in pain from 0 to 100%. Three lines represent each treatment group with distinct line styles.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar chart comparing responder rates (%) in two clinical studies (Study E1 and Study E3) for various doses of pregabalin versus placebo. The chart shows rates for placebo, 150 mg/day, 300 mg/day, and 600 mg/day in Study E1, and placebo, 600 mg/day, and 750 mg/day in Study E3, illustrating dose-dependent increases in responder rates.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A line graph depicting seizure reduction as median percent change from baseline against dose in mg/day. It compares four studies labeled E1 BID, E2 TID, E3 BID, and E3 TID with doses ranging up to 600 mg/day, showing statistically significant seizure reductions (p ≤ 0.0001) at increasing doses compared to placebo.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A bar chart displaying responder rates (%) for three groups: Placebo (22.6%, N=93), 2.5 mg/kg/day dosage (29.1%, N=103), and 10 mg/kg/day dosage (40.6%, N=96). The vertical axis represents responder rate percentage, ranging from 0 to 60%.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph showing percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. Four lines depict the effect of Pregabalin at daily doses of 600 mg, 450 mg, 300 mg, and placebo, illustrating comparative pain improvement among groups.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of pregabalin showing its molecular arrangement with an amino group, carbon chain, and carboxylic acid group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.